The Usefulness of the Ratio of Antigen–Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer

The Usefulness of the Ratio of Antigen–Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer

Autoantibodies against specific lung cancer-associated antigens have been suggested for the performance of lung cancer diagnosis. This study aimed to evaluate the diagnostic performance of the antigen–autoantibody immune complex (AIC) against its free antigens for CYFRA21-1, ProGRP, neutrophil gelat...

Full description

Bibliographic Details
Main Authors:	Heyjin Kim, Jin Kyung Lee, Ae-Chin Oh, Hye-Ryoun Kim, Young Jun Hong
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Diagnostics
Subjects:	lung cancer non-small cell lung cancer autoantibody biomarker CYFRA21-1 ProGRP
Online Access:	https://www.mdpi.com/2075-4418/13/18/2999

Similar Items

A rare case of Ewing sarcoma with elevated plasma pro-gastrin-releasing peptide (proGRP) level
by: Yoshitane Tsukamoto, MD, PhD, et al.
Published: (2016-12-01)

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm
by: Violetta Rosiek, et al.
Published: (2023-06-01)

Comparison Study of Cyfra 21-1, Carcinoembryonic Antigen and Telomerase Activity between Non Small Cell and Small Cell Lung Cancer Patients
by: Behrang Alani, et al.
Published: (2008-12-01)

Relationship of Tumor Markers and Hilar Lymph Nodes with Bone Metastasis of Whole Body Bone Imaging in Lung Adenocarcinoma
by: CAO Zhongnian, et al.
Published: (2019-02-01)

The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Cipto Mangunkusumo Hospital: A Retrospective Cohort Study
by: Cleopas Martin Rumende, et al.
Published: (2020-08-01)

Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer
by: Ning Li, et al.
Published: (2021-02-01)

9G Test<sup>TM</sup> Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening
by: Wonho Choe, et al.
Published: (2020-10-01)

Variability of serum CYFRA 21 − 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis
by: Asami Minamibata, et al.
Published: (2023-09-01)

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study
by: Narongchai Autsavapromporn, et al.
Published: (2021-11-01)

Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction
by: Jingmin Yuan, et al.
Published: (2022-06-01)

Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and neuron-specific enolase in liver metastases from elderly lung cancer patients
by: Tao Cheng, et al.
Published: (2022-09-01)

CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value
by: Garcia-Valdecasas Gayo Sonsoles, et al.
Published: (2020-10-01)

Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers
by: Takahiro Akita, et al.
Published: (2024-04-01)

Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients
by: Nikolaus A. Handke, et al.
Published: (2021-02-01)

Scratching the Surface—An Overview of the Roles of Cell Surface GRP78 in Cancer
by: Jack Chen, et al.
Published: (2022-05-01)

Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
by: Yirui Zhai, et al.
Published: (2020-09-01)

Diagnostic value of cyfra 21-1 and carcinoembryonic antigen in differentiation between benign and malignant pleural effusion
by: Waffa S. El-Shimy, et al.
Published: (2015-04-01)

Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients
by: Xinchun DUAN, et al.
Published: (2015-06-01)

Serum-based protein biomarkers for detection of lung cancer
by: Bhatnagar Shilpa, et al.
Published: (2014-04-01)

Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts
by: Shijie Wang, et al.
Published: (2024-01-01)

Diagnostic utilities of washout CYFRA 21-1 combined with washout thyroglobulin for metastatic lymph nodes in thyroid cancer: a prospective study
by: Joonseon Park, et al.
Published: (2024-03-01)

Evaluation of tumor markers carcinoembryonic antigen, cytokeratin 19 fragment and cancer-associated antigen 72-4 in neoplastic and non-neoplastic canine effusions differentiation
by: L.V. Teixeira, et al.
Published: (2014-10-01)

Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125
by: Chunjing Jin, et al.
Published: (2019-11-01)

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer
by: Juan Zhou, et al.
Published: (2021-03-01)

Serum CYFRA 21-1 in Egyptian women with breast cancer
by: Samia A. Ebied, et al.
Published: (2017-03-01)

Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study
by: Yuki Sato, MD, et al.
Published: (2023-12-01)

Correlation between Changes in Serum Level of CEA and CYFRA 21-1 and Objective Response of Chemotherapy
by: Xinlin MU, et al.
Published: (2009-09-01)

Lung cancer: Clinical implications
by: Jovanović Dragana
Published: (2007-01-01)

Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis
by: Chaiho Jeong, et al.
Published: (2021-02-01)

Early detection of lung cancer in a real-world cohort via tumor-associated immune autoantibody and imaging combination
by: Zhong Liu, et al.
Published: (2023-04-01)

Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations
by: Dat P. Ha, et al.
Published: (2022-11-01)

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis
by: Jiangyue Qin, et al.
Published: (2018-12-01)

Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization
by: Jianying Zhang, et al.
Published: (2022-07-01)

Diagnostic value of tumor associated autoantibody panel in early detection of lung cancer in Chinese population: Protocol for a prospective, observational, and multicenter clinical trial
by: Lin Tong, et al.
Published: (2022-12-01)

Rapid and quantitative detection of urinary Cyfra21-1 using fluorescent nanosphere-based immunochromatographic test strip for diagnosis and prognostic monitoring of bladder cancer
by: Qifang Lei, et al.
Published: (2019-12-01)

Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer
by: Hua-Hsi Wu, et al.
Published: (2014-03-01)

Positive Autoantibody Is Associated with Malignancies in Patients with Idiopathic Interstitial Pneumonias
by: Takuma Koga, et al.
Published: (2022-10-01)

Clinical Significance of Serum Cytokeratin 19 Fragment in the Prediction of Chemotherapy Efficacy and Prognosis in Patients with Advanced Non-small Cell Lung Cancer
by: Chong'an XU, et al.
Published: (2010-10-01)

Development of Diagnosis Model for Early Lung Nodules Based on a Seven Autoantibodies Panel and Imaging Features
by: Leidi Xu, et al.
Published: (2022-04-01)

Detection and Quantification of Tp53 and p53-Anti-p53 Autoantibody Immune Complex: Promising Biomarkers in Early Stage Lung Cancer Diagnosis
by: Keum-Soo Song, et al.
Published: (2022-02-01)